Search results
Showing 1 to 9 of 9 results for fluticasone
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .
This guideline sets out an antimicrobial prescribing strategy for acute sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sinusitis is usually caused by a virus, lasts for about 2 to 3 weeks, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)
NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .
Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)
This evidence summary has been updated and replaced by NICE guideline 115.
Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)
This evidence summary has been updated and replaced by NICE guideline NG80.
This evidence summary has been updated and replaced by NICE guideline 115.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)
This evidence summary has been updated and replaced by NICE guideline NG80.